Evolent Health Inc Stock Price, News & Analysis

Evolent Health (NYSE: EVH) has announced plans to offer $140.0 million in convertible senior notes due 2031, with an option for initial purchasers to acquire an additional $20.0 million. The company intends to use $100.0 million to repurchase a portion of its 1.50% convertible senior notes due 2025 and $40.0 million to repurchase Class A common stock.

The new notes, offered exclusively to qualified institutional buyers under Rule 144A, will be convertible into cash, Class A common stock, or a combination thereof. They will mature on August 15, 2031, with semiannual interest payments beginning February 15, 2026. Evolent maintains the right to terminate conversion rights after August 20, 2026, subject to specific stock price conditions.

Evolent Health (NYSE:EVH) reported Q2 2025 financial results with revenue of $444.3 million, down from $647.1 million in Q2 2024. The company posted a net loss of $51.1 million, compared to a $6.4 million loss in the prior year. Despite the revenue decline, Adjusted EBITDA margin improved to 8.5% from 8.0% year-over-year.

The company announced four new revenue agreements in Q2, bringing the year-to-date total to 11. For Q3 2025, Evolent expects revenue between $460-480 million and Adjusted EBITDA of $34-42 million. Full-year 2025 guidance was revised, with revenue projected at $1.85-1.88 billion and Adjusted EBITDA expected between $140-165 million.

Management highlighted strong customer retention and accelerating pipeline growth, expecting to exceed historical growth rates for 2026.

Evolent Health (NYSE:EVH), a healthcare company focused on complex conditions management, has scheduled its Q2 2025 earnings release for August 7, 2025, after market close. The company will host a conference call at 5:00 PM ET the same day.

Shareholders can access the live broadcast through Evolent's investor relations website. Analysts can participate by dialing 855.940.9467 (US) or 412.317.6034 (International). Additionally, EVH's management team will present at the Canaccord Genuity 44th Annual Growth Conference in Boston on August 13, 2025.

Evolent Health (NYSE: EVH) announced two key leadership appointments to strengthen its clinical and financial teams. Dr. David Lim joins as chief clinical officer, bringing extensive experience in value-based care and healthcare technology. He will lead Evolent's 300-person medical team and report to CMO Dr. Von Nguyen.

John Way has been appointed as CFO of Performance Suite, overseeing financial aspects of the company's at-risk specialty condition management products. Way brings over 20 years of executive financial experience, including roles as CFO at OptumHealth and OptumCare, and will report to CFO John Johnson.

Evolent Health (NYSE: EVH) has reaffirmed its Q2 2025 Adjusted EBITDA guidance of $33M-$40M and full year guidance of $135M-165M, citing below-expected oncology cost trends through May 2025. CFO John Johnson expressed confidence in meeting or exceeding Q2 expectations, suggesting performance could reach the upper half of the guidance range if current trends persist. The company secured a Commitment Letter with Ares Management Credit funds for potential additional non-dilutive financing to address 2025 Convertible Notes and support working capital needs. CEO Seth Blackley highlighted a significant increase in their 2026 revenue bookings forecast due to accelerating business development activities.

Evolent Health (NYSE: EVH) reported its Q1 2025 financial results, with revenue of $483.6 million, down from $639.7 million in Q1 2024. The company posted a net loss of $72.3 million ($0.63 per share), compared to a loss of $25.2 million ($0.22 per share) in the prior year. Adjusted EBITDA was $36.9 million with a 7.6% margin. The company announced five new revenue agreements, including two health plans implementing surgical management solutions, expansion of medical oncology services, and growth in imaging and musculoskeletal services. Despite the wider losses, management reiterated its full-year 2025 guidance, expecting revenue between $2.06-2.11 billion and adjusted EBITDA of $135-165 million. For Q2 2025, Evolent projects revenue of $440-470 million and adjusted EBITDA of $33-40 million.

Evolent Health (NYSE: EVH) has nominated Shawn Guertin, former CFO of CVS Health, Aetna, and Coventry Health Care, to its Board of Directors. The election will take place at the annual stockholders meeting on June 5, 2025. Guertin, who brings nearly 40 years of actuarial, financial, and management experience, served as Executive Vice President and CFO at CVS Health from May 2021 to October 2023.

If elected, Guertin will become the sixth new independent director added to the Board in the past four years, replacing Diane Holder who is not seeking re-election after 14 years of service. This nomination continues Evolent's board refreshment efforts to align with best-in-class corporate governance practices.

Evolent Health has reported significant success in reducing the use of low-value oncology treatment regimens by over 20% through their provider education and engagement campaign. The program, detailed in the Journal of Clinical Pathways, focuses on identifying and decreasing the use of treatments that may have lower survival rates, more severe side effects, or excessive costs without additional clinical benefits.

The initiative spans therapies across 10 common cancer types, representing about 1% of all requests. In one striking example, a low-value lung cancer regimen was found to be approximately 70 times more expensive ($40,000 more per quarter) than a preferred alternative, without supporting evidence for better clinical outcomes.

From February through May 2024, the program achieved a 20.1% reduction in low-value regimen usage compared to the same period in 2023, with provider requests for such regimens dropping by 15.5%. The success was attributed to a comprehensive approach combining provider education, technology-enabled clinical decision support, and performance incentives.

Evolent Health (NYSE: EVH) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, after market close, followed by a conference call at 5 p.m. ET. Shareholders can access the live broadcast through Evolent's investor relations website.

Analysts can participate in the Q&A session by dialing 855.940.9467 (412.317.6034 for international callers). The company's management team will also attend several upcoming investor conferences, including:

• Needham 20th Annual Technology, Media and Consumer Conference (Virtual) - May 12, 2025
• RBC Global Health Care Conference in New York - May 21, 2025
• William Blair 45th Annual Growth Stock Conference in Chicago - June 3, 2025
• Citizens JMP Medical Devices and Healthcare Services Forum in Boston - June 17, 2025